Abbott Labs - stabiler Dividendenwert (Seite 13)

[ONYXLeader]

Antwort auf Beitrag Nr.: 41.179.906 von Bajuwar am 10.03.11 17:52:03

Hallo zusammen,

bin mit 34,50 Euro mal mit nur 90 Stück rein.
Mal schauen, was da demnächst draus wird.
Charttechnisch schaut es ja gar nicht só schlecht aus, oder was meint Ihr?

Gruß ONYX

[Bajuwar]

bin mit investiert und plane nachkäufe

[Imba]

Hi,
ich bin auch dabei.

[Tamakoschy]

Antwort auf Beitrag Nr.: 41.087.308 von ONYXLeader am 22.02.11 20:48:22

Ich bin mit einer Anfangsposition dabei. Hast Du vielleicht auch MDT? Die haben heute auch gute Zahlen geliefert.

[ONYXLeader]

Antwort auf Beitrag Nr.: 40.864.921 von R-BgO am 14.01.11 17:54:44

Hallo,

habe heute von einem Banker die Abbott empfohlen bekommen.
Bin dann zu 34,50 Euro gleich rein.
mal schauen, ob das ein guter Tipp war.

Wer ist da noch so alles investiert?

Gruß ONYX

[R-BgO]

Psoriasis Drug Setback Highlights Abbott Pipeline Weaknesses
January 18, 2011 | about: ABT / JNJ


Abbott Laboratories’ (ABT) next big thing may not be coming at all. The company has announced that it is withdrawing psoriasis drug briakinumab from US and European regulatory review, dashing expectations that the monoclonal antibody would hit the market next year and put some luster on an otherwise moribund pipeline.

Shares in the Illinois group fell 1% to $46.89 Friday on the news of the likely end of Abbott’s biggest pipeline hope. Prospects for the drug have been shrinking over time, but this is not good news for a company that has had its share of recent setbacks and patent threats (Astra pulls plug on Certriad, December 23, 2010.)

Disappointment

The company announced in a securities filing that it was withdrawing the candidate after discussions with authorities that indicated the “need for further analysis and the potential for additional studies.” This decision signals Abbott's uncertainty that the product can ever be a clinical or commercial success.

Known also by the research code ABT-874, briakinumab was rated as a key asset for Abbott, the most valuable product in its pipeline (The world's most valuable pipeline products, April 18, 2008). Current consensus forecast sales of $358m give it a net present value of $950m, or 1% of Abbott’s market capitalization of $73.4bn at Thursday’s close.

However it has fallen two years behind Johnson & Johnson’s (JNJ) Stelara, which like briakinumab suppresses the cytokines interleukin-12 and -23 to dampen the autoimmune responses that result in psoriasis (Belated Stelara approval should be worth the wait, September 29, 2008). Launched in late 2008, Stelara is forecast to be a blockbuster before 2016, when it is slated to generate $1.25bn in worldwide sales and is seen as a challenger to Abbott’s Humira in the psoriasis indication.

This is one of the reasons expectations have been receding for briakinumab; EvaluatePharma consensus for 2014 has shrunk by half over the past year, to $226m. This news will almost surely result in many analysts eliminating briakinumab from their forecasts.

Weakness

The size of the investor reaction was largely in line with briakinumab’s value to Abbott. While pipeline setbacks can often have a more damaging effect on market cap, even for a big pharma firm, the measured reaction on Friday likely reflects already diminished expectations.

Still, Abbott's pipeline could do with a success story. In Humira, the group does have the product forecast to be the world’s largest seller in 2016; however, it loses patent protection that year, putting $9bn in sales at risk thereafter.

Moreover, other than Humira, Abbott had only two other launches in the last decade that achieved blockbuster status – TriCor and Kaletra – with Kaletra also set to lose patent protection in 2016. Meanwhile, the company only has two other drugs in the pipeline that are forecast to achieve at least $100m in sales by 2016: parpoprunox and ABT-263.

Thus, the briakinumab setback highlights the weaknesses in Abbott’s pipeline. While it is one that would harm a pure-play pharmaceutical company more than a diversified group like Abbott, a success would have helped secure future growth for its pharma division, beyond Humira.

[R-BgO]

http://seekingalpha.com/article/211357-abbott-laboratories-a…

[R-BgO]

derzeit knapp unter 4%; aufgrund der vielen eingeschlafenen Threads schließe ich, dass in Deutschland nicht sehr populär...



Corporate Profile
Founded in 1888 by Dr. Wallace Abbott, a Chicago physician, Abbott is a broad-based health care company that discovers, develops, manufactures and markets products and services that span the continuum of care – from prevention and diagnosis to treatment and cure. Abbott's principal businesses are global pharmaceuticals, nutritional and medical products, including diagnostics and cardiovascular devices.

Headquartered in north suburban Chicago, Abbott serves customers in more than 130 countries, with an employee base of nearly 90,000 at more than 100 manufacturing, distribution, research and development, and other locations around the world.

The principal market for Abbott’s common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the United States, Abbott’s shares are listed on the London Stock Exchange and the Swiss Stock Exchange.